Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Expands By 153.2%

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 481,974 shares, a growth of 153.2% from the July 15th total of 190,323 shares. Based on an average daily trading volume, of 1,706,839 shares, the short-interest ratio is presently 0.3 days. Approximately 4.1% of the company’s shares are sold short.

BiomX Stock Up 4.5%

Shares of PHGE stock opened at $0.15 on Friday. The firm has a market capitalization of $1.83 million, a price-to-earnings ratio of -0.05 and a beta of 1.35. The stock has a fifty day moving average of $0.33 and a 200 day moving average of $2.37. BiomX has a 52 week low of $0.12 and a 52 week high of $12.29.

BiomX (NYSEAMERICAN:PHGE) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. Equities research analysts anticipate that BiomX will post -5.85 earnings per share for the current year.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 40.57% of the company’s stock.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.